Key Insights

Highlights

Success Rate

75% trial completion

Treatment Research

6 treatments under study, led by Cognitive Assessment

Research Leaders

5 sponsors active, led by Virginia Commonwealth University

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 87/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

75.0%

-11.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

75% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (2)
Phase 1 (1)

Trial Status

Completed3
Terminated1

Trial Success Rate

75.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT06926972Not ApplicableCompletedPrimary

NutritiOUs fRuIts and veggieS to Improve Health: A Culinary Medicine Intervention

NCT03621124TerminatedPrimary

Maladaptive Adipose Tissue Activity in Cancer

NCT03052868Not ApplicableCompletedPrimary

Analysis of Neurocognitive Elements of Attention After Chemotherapy

NCT01750580Phase 1CompletedPrimary

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

Showing all 4 trials

Research Network

Common Treatments

  • Cognitive Assessment1
  • Resting Energy Expenditure1
  • Thermal Comfort Questionnaire1
  • Lirilumab1
  • Nourish1

Active Sponsors

  • Virginia Commonwealth University1
  • University of Texas Southwestern Medical Center1
  • Bristol-Myers Squibb1
  • National Cancer Institute (NCI)1
  • H. Lee Moffitt Cancer Center and Research Institute1

Top Investigators

Activity Timeline